标题
Gilteritinib overcomes lorlatinib resistance in ALK-rearranged cancer
作者
关键词
-
出版物
Nature Communications
Volume 12, Issue 1, Pages -
出版商
Springer Science and Business Media LLC
发表日期
2021-02-24
DOI
10.1038/s41467-021-21396-w
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Drug resistance mechanisms in Japanese anaplastic lymphoma kinase‐positive non–small cell lung cancer and the clinical responses based on the resistant mechanisms
- (2020) Noriko Yanagitani et al. CANCER SCIENCE
- Overcoming resistance by ALK compound mutation (I1171S + G1269A) after sequential treatment of multiple ALK inhibitors in non‐small cell lung cancer
- (2020) Ken Takahashi et al. Thoracic Cancer
- Lorlatinib: an additional option for ALK-positive non-small cell lung cancer?
- (2020) Alice Mogenet et al. Translational Lung Cancer Research
- Therapy-Induced Evolution of Human Lung Cancer Revealed by Single-Cell RNA Sequencing
- (2020) Ashley Maynard et al. CELL
- First-Line Lorlatinib or Crizotinib in Advanced ALK-Positive Lung Cancer
- (2020) Alice T. Shaw et al. NEW ENGLAND JOURNAL OF MEDICINE
- AXL confers intrinsic resistance to osimertinib and advances the emergence of tolerant cells
- (2019) Hirokazu Taniguchi et al. Nature Communications
- Prediction of ALK mutations mediating ALK-TKIs resistance and drug re-purposing to overcome the resistance
- (2019) Koutaroh Okada et al. EBioMedicine
- Updated Efficacy and Safety Data and Impact of the EML4-ALK Fusion Variant on the Efficacy of Alectinib in Untreated ALK-positive Advanced Non-small-cell Lung Cancer in the Global Phase III ALEX Study
- (2019) D. Ross Camidge et al. Journal of Thoracic Oncology
- Treatment with Next-Generation ALK Inhibitors Fuels Plasma ALK Mutation Diversity
- (2019) Ibiayi Dagogo-Jack et al. CLINICAL CANCER RESEARCH
- Acquired Resistance Mutations to ALK Inhibitors Identified by Single Circulating Tumor Cell Sequencing in ALK-Rearranged Non–Small-Cell Lung Cancer
- (2019) Emma Pailler et al. CLINICAL CANCER RESEARCH
- Diverse Resistance Mechanisms to the Third-Generation ALK Inhibitor Lorlatinib in ALK-Rearranged Lung Cancer
- (2019) Gonzalo Recondo et al. CLINICAL CANCER RESEARCH
- Targeting YAP to overcome acquired resistance to ALK inhibitors in ALK ‐rearranged lung cancer
- (2019) Mi Ran Yun et al. EMBO Molecular Medicine
- Final progression-free survival results from the J-ALEX study of alectinib versus crizotinib in ALK-positive non-small-cell lung cancer
- (2019) Kazuhiko Nakagawa et al. LUNG CANCER
- Enhancer remodeling and microRNA alterations are associated with acquired resistance to ALK inhibitors
- (2018) Mi Ran Yun et al. CANCER RESEARCH
- Foretinib Overcomes Entrectinib Resistance Associated with theNTRK1G667C Mutation inNTRK1Fusion–Positive Tumor Cells in a Brain Metastasis Model
- (2018) Akihiro Nishiyama et al. CLINICAL CANCER RESEARCH
- ALKALs are in vivo ligands for ALK family receptor tyrosine kinases in the neural crest and derived cells
- (2018) Andrey Fadeev et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Sequential ALK Inhibitors Can Select for Lorlatinib-Resistant Compound ALK Mutations in ALK-Positive Lung Cancer
- (2018) Satoshi Yoda et al. Cancer Discovery
- Overcoming drug-tolerant cancer cell subpopulations showing AXL activation and epithelial–mesenchymal transition is critical in conquering ALK-positive lung cancer
- (2018) Shinji Nakamichi et al. Oncotarget
- Heat shock protein 90 inhibitors overcome the resistance to Fms-like tyrosine kinase 3 inhibitors in acute myeloid leukemia
- (2018) Kazuhiro Katayama et al. Oncotarget
- Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study
- (2018) Benjamin J Solomon et al. LANCET ONCOLOGY
- Gilteritinib, a FLT3/AXL inhibitor, shows antileukemic activity in mouse models of FLT3 mutated acute myeloid leukemia
- (2017) Masamichi Mori et al. INVESTIGATIONAL NEW DRUGS
- Alectinib versus crizotinib in patients with ALK -positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial
- (2017) Toyoaki Hida et al. LANCET
- Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial
- (2017) Alice T Shaw et al. LANCET ONCOLOGY
- Mechanisms of Resistance to NTRK Inhibitors and Therapeutic Strategies in NTRK1-Rearranged Cancers
- (2017) Miho J. Fuse et al. MOLECULAR CANCER THERAPEUTICS
- Alectinib versus Crizotinib in Untreated ALK-Positive Non–Small-Cell Lung Cancer
- (2017) Solange Peters et al. NEW ENGLAND JOURNAL OF MEDICINE
- Brigatinib combined with anti-EGFR antibody overcomes osimertinib resistance in EGFR-mutated non-small-cell lung cancer
- (2017) Ken Uchibori et al. Nature Communications
- Prospective Comprehensive Molecular Characterization of Lung Adenocarcinomas for Efficient Patient Matching to Approved and Emerging Therapies
- (2017) Emmet J. Jordan et al. Cancer Discovery
- Targeting ALK: Precision Medicine Takes on Drug Resistance
- (2017) Jessica J. Lin et al. Cancer Discovery
- The Effect of Conformational Flexibility on Binding Free Energy Estimation between Kinases and Their Inhibitors
- (2016) Mitsugu Araki et al. Journal of Chemical Information and Modeling
- Deep Phosphotyrosine Proteomics by Optimization of Phosphotyrosine Enrichment and MS/MS Parameters
- (2016) Yuichi Abe et al. JOURNAL OF PROTEOME RESEARCH
- Transformation to SCLC after Treatment with the ALK Inhibitor Alectinib
- (2016) Shiro Fujita et al. Journal of Thoracic Oncology
- Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F
- (2016) Alice T. Shaw et al. NEW ENGLAND JOURNAL OF MEDICINE
- Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer
- (2016) J. F. Gainor et al. Cancer Discovery
- PF-06463922, an ALK/ROS1 Inhibitor, Overcomes Resistance to First and Second Generation ALK Inhibitors in Preclinical Models
- (2015) Helen Y. Zou et al. CANCER CELL
- RAS-MAPK dependence underlies a rational polytherapy strategy in EML4-ALK–positive lung cancer
- (2015) Gorjan Hrustanovic et al. NATURE MEDICINE
- Acquired Resistance to the TRK Inhibitor Entrectinib in Colorectal Cancer
- (2015) M. Russo et al. Cancer Discovery
- First-Line Crizotinib versus Chemotherapy in ALK-Positive Lung Cancer
- (2014) Benjamin J. Solomon et al. NEW ENGLAND JOURNAL OF MEDICINE
- ALKin Lung Cancer: Past, Present, and Future
- (2013) Alice T. Shaw et al. JOURNAL OF CLINICAL ONCOLOGY
- Genetic alterations defining NSCLC subtypes and their therapeutic implications
- (2013) Larissa A. Pikor et al. LUNG CANCER
- Epithelial-mesenchymal transition leads to crizotinib resistance in H2228 lung cancer cells with EML4-ALK translocation
- (2013) Hyeong Ryul Kim et al. Molecular Oncology
- Crizotinib versus Chemotherapy in Advanced ALK-Positive Lung Cancer
- (2013) Alice T. Shaw et al. NEW ENGLAND JOURNAL OF MEDICINE
- Paracrine Receptor Activation by Microenvironment Triggers Bypass Survival Signals and ALK Inhibitor Resistance in EML4-ALK Lung Cancer Cells
- (2012) T. Yamada et al. CLINICAL CANCER RESEARCH
- Mechanisms of Resistance to Crizotinib in Patients withALKGene Rearranged Non–Small Cell Lung Cancer
- (2012) Robert C. Doebele et al. CLINICAL CANCER RESEARCH
- Mechanisms of Acquired Crizotinib Resistance in ALK-Rearranged Lung Cancers
- (2012) R. Katayama et al. Science Translational Medicine
- EML4-ALK Mutations in Lung Cancer That Confer Resistance to ALK Inhibitors
- (2010) Young Lim Choi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Massively parallel computation of absolute binding free energy with well-equilibrated states
- (2009) Hideaki Fujitani et al. PHYSICAL REVIEW E
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search